Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial

DiscussionEven though the new oral anticoagulants seem to be both safe and effective, few clinical trials have been carried out to test their effect on non-disabling cerebrovascular events. Treatment with rivaroxaban may prevent more cerebrovascular events with an acceptable risk profile after TIA or minor stroke, compared with aspirin, thus helping to improve the outcome of the disease.Trial registrationNo. NCT01923818

Source: BMC Neurology - October 12, 2015 Category: Neurology Authors: Fang YangWenrui JiangYa BaiJunliang HanXuedong LiuGuangyun ZhangGang Zhao Source Type: research